CD&R and McKesson agree to acquire Option Care Health in $5.8 billion deal

CD&R and McKesson will acquire Option Care Health for $32.05 per share, valuing the company at $5.8 billion including debt. The deal, expected to close in early 2027, gives CD&R majority ownership and McKesson a 49% stake. Option Care's Q2 revenue rose 1.9% to $1.442 billion, with net income up 6.7% to $53.9 million.

Original reporting
Published Oct 6, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 2:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CD&R and McKesson agree to acquire Option Care Health in $5.8 billion deal — source image
Decision brief

The 30-second read

$OPCHBullishHigh
01

Why it matters

The transaction creates a vertically integrated platform for drug, equipment, and clinical support services, potentially improving margins but also adding execution risk.

02

Market read

The announcement is a material M&A event in the healthcare sector, likely moving Option Care shares sharply and prompting sector re‑valuation.

03

What to watch

Regulatory scrutiny of home infusion reimbursement could affect long‑term profitability.

Relevance 9/10Novelty 9/10Timing: announcement today

Background

The deal combines a private equity firm (CD&R) with a major healthcare distributor (McKesson) to acquire a leading home infusion provider.

Company-level read

Ticker impact

$OPCHBullishHigh confidence
Context

Option Care Health announced a $5.8 billion acquisition by CD&R and McKesson at $32.05 per share, a 37% premium to the prior close.

Expected impact

upward pressure as the market prices in the 37% premium

Evidence & confidence

The deal price is above market, providing immediate upside for shareholders.

$MCKNeutralMedium confidence
Context

McKesson will invest about $1.4 billion for a 49% stake in Option Care Health as part of the $5.8 billion transaction.

Expected impact

limited impact, likely flat to slight dip due to cash deployment

Evidence & confidence

The investment is sizable but does not directly affect McKesson's core earnings; market reaction may be muted.

Market effects

Consolidates the home infusion market, potentially prompting further M&A activity in healthcare services.

U.S. healthcare sector may see a modest uplift as investors reassess valuation of similar providers.

Highlights private equity's continued appetite for large-scale healthcare acquisitions worldwide.

Counterpoint

The premium may be excessive if integration costs rise, suggesting a possible overvaluation.

Key entities

  • CD&R

    Lead investor acquiring a controlling stake in Option Care Health.

  • Option Care Health

    Home infusion services provider being acquired.

  • McKesson

    Healthcare distributor taking a 49% stake in the transaction.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.